Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
FAIL · Does not pass the screen
34.18 USD
At the last full screen 2026-09-02
Screened 2026-09-02 · the tape above runs as of 17:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Roivant Sciences Ltd holds its Markup at $34.18. Elevated stress, defensive posture warranted, held for 10 days.
As held on the ledger · 2026-09-02
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 10 days
Price at the screen
$34.18
Valuation
N/A trailing · -19.90 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.13
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.88%
Below 33%
Interest-bearing debt is just 1.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
50.32%
Below 33%
Interest-bearing cash and securities are 50.3% of assets, above the one-third limit.
Fail
Receivables
38.35%
Below 49%
Money owed to the company is 38.4% of assets, under the 49% limit.
Pass
Revenue purity
2,156.28%
Below 5%
2,156.3% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-02 screen. The gold marker is the market price at the same screen. A 20.0% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +20% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical bets rarely survive revenue cliffs
Picture a lab team watching a single antibody candidate move through trials while last year's sales evaporate. Roivant is exactly that story, a clinical stage biotech chasing IMVT-1402 and similar molecules with revenue already down 67 percent and margins stuck at zero.
We pass because the numbers refuse to support the analyst chorus. Forward earnings sit at a negative 22 times, return on equity is negative 8 percent, and the narrow moat offers little protection if the pipeline stumbles. A 16 percent gap to fair value looks tempting until you remember these are peak hopes priced in, not repeatable cash flow.
The real exposure sits in binary trial outcomes and repeated cash needs that can wipe out any margin of safety overnight. Ethical screen clears, yet the business remains a classic development gamble where low multiples signal distress more than value.
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ROIV trades on NASDAQ (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-11Markup$34.18+1.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39.
2026-08-11Markup$33.84+12.6%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39.
2026-07-18Markup$30.04+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 150%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (12 analysts) rates it strong buy, with a mean price target of $39.
2026-07-03Markup$30.04+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$30.04Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.